



Silver State Scripts Board

Meeting Minutes

Date of Meeting: Thursday, December 9, 2021, at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Scripts Board.

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|-------------------------------------|---------|--------|---------------------------------|-------------------------------------|--------------------------|---------------------|--------------------------|-------------------------------------|------------------------|-------------------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|------------------------|--------------------------|-------------------------------------|------------------|-------------------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|---|
| Closed Executive Session | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Financial Review of Drug Classes with Proposed Changes | <p>Chairman Decerbo called the meeting to order at 1:00 PM on December 9, 2021.</p> <p>Roll was taken by Chairman Decerbo.</p> <table border="0" data-bbox="653 933 1396 1299"> <thead> <tr> <th></th> <th>Present</th> <th>Absent</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Passalacqua, Brian, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>A quorum was present.</p> | | Present | Absent | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Adashek, Joseph, MD | <input type="checkbox"/> | <input checked="" type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Passalacqua, Brian, MD | <input type="checkbox"/> | <input checked="" type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <p>The DHCFP Staff Present were as follows:</p> <p>Olsen, David, Social Services Chief III</p> <p>Gudino, Antonio, Social Services Program Specialist III</p> <p>Flowers, Ellen, Program Officer I</p> <p>Lither, Gabriel, Senior Deputy Attorney General (SDAG)</p> <p>Gainwell Technologies Staff Present were as follows:</p> <p>Leid, Jovanna, Pharm.D.</p> |
| | Present | Absent | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Adashek, Joseph, MD | <input type="checkbox"/> | <input checked="" type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Passalacqua, Brian, MD | <input type="checkbox"/> | <input checked="" type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes |
|-------------|--|---|
| | <p>Chairman Decerbo directed Kevin Whittington to proceed with the financial review of drug classes with proposed changes up for review during the fourth Quarter Silver State Scripts Board meeting.</p> <p>Mr. Whittington reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside of this closed session of the Silver States Scripts Board meeting.</p> <p>Mr. Whittington presented the financial review of the Cardiovascular Agents - Miscellaneous Cardiac Agents noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the financial review of the Electrolytic and Renal Agents – Potassium Removing Agents noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the financial review of the Neurological Agents – Movement Disorders class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the financial review of the Genitourinary Agents – Bladder Antispasmodics class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the financial review of the Hormones and Hormone Modifiers – Anti-Hypoglycemic Agents noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the financial review of the Neurological Agents – Anti-Migraine Agents – CGRP Receptor Antagonists class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the financial review of the Ophthalmic Agents – Ophthalmic for Dry Eye Disease class, noting the products with proposed changes in PDL status.</p> | <p>OptumRx Staff Present were as follows: Whittington, Kevin, R.Ph. LeCheminant, Jill, Pharm.D. Chien, Michael, Pharm.D. Piccirilli, Annette Medina, Daniel</p> |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | |
|---------------------------------|---|-------------------------------------|---------|--------|---------------------------------|-------------------------------------|--------------------------|---------------------|--------------------------|-------------------------------------|------------------------|-------------------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--|
| | <p>Mr. Whittington presented the financial review of the Psychotropic Agents - Atypical Antipsychotics, Injectable class noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the financial review of the Psychotropic Agents - Atypical Antipsychotics, Oral/Topical class, noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the financial review of the Toxicology Agents - Opiate Antagonists noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the financial review of the Analgesics - Analgesic/Miscellaneous - Neuropathic Pain/Fibromyalgia Agents noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the financial review of the Cardiovascular Agents - Antihypertensive Agents - Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), noting the products with proposed changes in PDL status.</p> <p>Mr. Whittington presented the financial review of the Hormones and Hormone Modifiers - Antidiabetic Agents - Incretin Mimetics noting the products with proposed changes in PDL status.</p> | | | | | | | | | | | | | | | | | | | |
| Open Public Meeting | | | | | | | | | | | | | | | | | | | | |
| 1. Call to Order and Roll Call | <p>Chairman Decerbo called the meeting to order at 1:50 PM on December 9, 2021.</p> <p>Roll was taken by Chairman Decerbo.</p> <table data-bbox="651 1153 1407 1395"> <thead> <tr> <th></th> <th>Present</th> <th>Absent</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Present | Absent | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Adashek, Joseph, MD | <input type="checkbox"/> | <input checked="" type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <p>The DHCFP Staff Present were as follows:</p> <p>Olsen, David, Social Services Chief III</p> <p>Gudino, Antonio, Social Services Program Specialist III</p> <p>Flowers, Ellen, Program Officer I</p> <p>Lither, Gabriel, SDAG</p> |
| | Present | Absent | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | |
| Adashek, Joseph, MD | <input type="checkbox"/> | <input checked="" type="checkbox"/> | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes |
|---|---|--|
| | <p>Passalacqua, Brian, MD <input type="checkbox"/> <input checked="" type="checkbox"/></p> <p>Singh, Aditi, MD <input checked="" type="checkbox"/> <input type="checkbox"/></p> <p>Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/></p> <p>A quorum was present.</p> | <p>Gainwell Technologies Staff Present were as follows: Leid, Jovanna, Pharm.D.</p> <p>OptumRx Staff Present were as follows: LeCheminant, Jill, Pharm.D. Kiriakopoulos, Amanda, Pharm.D. Whittington, Kevin, R.Ph. Chien, Michael, Pharm.D. Piccirilli, Annette Medina, Daniel</p> <p>The public attendee list is included as Attachment A.</p> <p>Note: Participants may not have chosen to reveal their identity. The accuracy of the attendee list is not assured.</p> |
| <p>2. Public Comment on Any Matter on the Agenda.</p> | <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Ms. Robin Reedy from the mental health advocacy group National Alliance on Mental Illness (NAMI). Ms. Reedy noted that NAMI supports open access to all mental health agents by qualified health care professionals. She commented that they believe prescribers should be permitted to choose the most appropriate agent without prior authorization (PA) as it can worsen outcomes in patients.</p> <p>Comment was provided by Dr. Brian Wensel from Sanovi Pharmaceuticals. He requested Kynmobi be reviewed at the next Board meeting as it was not</p> | |

| Agenda Item | Record | Notes |
|--|--|---|
| | included in this meeting for review. Chairman Decerbo commented that he would request OptumRx to include this in the next review. | |
| 3. Administrative | | |
| a. For Possible Action: Review and Approve Meeting Minutes from September 23, 2021. | No corrections were offered. The minutes were approved by unanimous consent. | |
| b. Status Update by the DHCFP. | Chief David Olsen discussed the start date of July 1, 2022, for Magellan Medicaid Administration as Nevada's new pharmacy benefit manager (PBM). | Referenced web addresses: The Nevada Department of Health and Human Services, Division of Health Care Financing and Policy Provider Portal https://www.medicaid.nv.gov The Division of Health Care Financing and Policy http://dhcftp.nv.gov |
| 4. Proposed New Drug Classes | | |
| a. For Possible Action: Discussion and possible adoption of Cardiovascular Agents - Miscellaneous Cardiac Agents | | |
| i. Public comment. | Telephonic and web comment was called for, and the phone lines were opened. Comment was made by Dr. Melissa Sommers with Novartis to discuss Entresto. She commented that pediatric patients were not included in the PA criteria during the Drug Utilization Review (DUR) Board meeting. Dr. Jill LeCheminant noted that the age limit would be updated in the PA criteria to meet the indication. | |

| Agenda Item | Record | | | | | | | | | | | | | | | | | |
|---|---|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|--|
| <p>ii. Drug class review presentation by OptumRx.</p> | <p>Dr. LeCheminant discussed the products within the drug class, including Entresto, Corlanor, and Verquvo. She provided indications for each agent. Dr. LeCheminant mentioned that Entresto and Corlanor are already managed via prior authorization. She noted that the criteria for Verquvo would be presented to the DUR Board.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p> | | | | | | | | | | | | | | | | | |
| <p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p> | <p>Chairman Decerbo noted that while these agents are not necessarily therapeutically equivalent, the class is miscellaneous cardiac agents, and it is helpful to have them grouped together. Chairman Decerbo asked Mr. Whittington to speak regarding the financial implications of separating the class. Mr. Whittington commented from a financial standpoint, separating the agents in the class would not impact the financials. Chairman Decerbo stated he did not have an issue with voting them as equivalent to keep them in one group. Board Member Ward commented that if in the future other agents are added to the class that is not used to treat heart failure, it may confuse as the agents would not treat the same disease state. Chairman Decerbo suggested renaming the class to Miscellaneous Heart Failure Agents.</p> <p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent with a class name update to Miscellaneous Heart Failure Agents.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="651 1234 1554 1388"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| | Khurana, Sapandeep, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Singh, Aditi, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iv. Presentation of recommendations for PDL inclusion by OptumRx. | Dr. LeCheminant recommended adding Corlanor and Entresto as preferred and Verquvo as non-preferred. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL. | Board Member Ward moved to accept the proposed changes. Board Member Khurana seconded the motion. A vote was held: <table border="0" data-bbox="636 690 1572 971"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| b. For Possible Action: Discussion and possible adoption of Electrolytic and Renal Agents – Potassium Removing Agents | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| i. Public comment. | Telephonic and web comment was called for, and the phone lines were opened. No public comment was offered. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| ii. Drug class review presentation by OptumRx. | <p>Dr. LeCheminant cited that in this new class Lokelma, sodium polystyrene sulfonate, SPS, and Veltassa would be reviewed. She provided their clinical indications and the limitations of SPS.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class. | <p>Chairman Decerbo moved to accept the list is clinically and therapeutically equivalent.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 667 1503 951"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iv. Presentation of recommendations for PDL inclusion by OptumRx. | <p>Dr. LeCheminant recommended the Board add Lokelma, sodium polystyrene sulfonate, and SPS as preferred. She recommended the Board add Veltassa as non-preferred.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL. | <p>Chairman Decerbo moved to accept the proposed updates as presented.</p> <p>Board Member Singh seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 1284 1503 1396"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | |
|---|--|--------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| | <table border="0"> <tr> <td data-bbox="663 240 930 269">Hautekeet, Mike, R.Ph</td> <td data-bbox="1184 240 1213 269"><input checked="" type="checkbox"/></td> <td data-bbox="1310 240 1339 269"><input type="checkbox"/></td> <td data-bbox="1436 240 1465 269"><input type="checkbox"/></td> </tr> <tr> <td data-bbox="663 282 968 311">Khurana, Sapandeep, MD</td> <td data-bbox="1184 282 1213 311"><input checked="" type="checkbox"/></td> <td data-bbox="1310 282 1339 311"><input type="checkbox"/></td> <td data-bbox="1436 282 1465 311"><input type="checkbox"/></td> </tr> <tr> <td data-bbox="663 324 856 354">Singh, Aditi, MD</td> <td data-bbox="1184 324 1213 354"><input checked="" type="checkbox"/></td> <td data-bbox="1310 324 1339 354"><input type="checkbox"/></td> <td data-bbox="1436 324 1465 354"><input type="checkbox"/></td> </tr> <tr> <td data-bbox="663 367 926 396">Ward, Kate, Pharm.D.</td> <td data-bbox="1184 367 1213 396"><input checked="" type="checkbox"/></td> <td data-bbox="1310 367 1339 396"><input type="checkbox"/></td> <td data-bbox="1436 367 1465 396"><input type="checkbox"/></td> </tr> </table> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | |
| <p>c. For Possible Action: Discussion and possible adoption of Neurological Agents – Movement Disorders</p> | | | | | | | | | | | | | | | | | | |
| <p>i. Public comment.</p> | <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Ms. Reedy from the mental health advocacy group NAMI. She noted that NAMI supports open access to all mental health agents, including agents utilized to manage medication side effects such as tardive dyskinesia. She advocated for open access for agents that would prevent side effect issues.</p> <p>Comment was provided by Dr. Jennifer Shear from Teva Pharmaceuticals Medical Affairs. She wanted to clarify the boxed warning with Austedo and noted it was for patients with Huntington’s Disease and not tardive dyskinesia.</p> <p>Comment was provided by Dr. Ed Paiewonsky from Neurocrine Biosciences. He made himself available for questions.</p> <p>Dr. LeCheminant notified the Board that a letter was provided for review requesting Ingrezza have preferred status.</p> | | | | | | | | | | | | | | | | | |
| <p>ii. Drug class review presentation by OptumRx.</p> | <p>Dr. LeCheminant discussed Austedo, Ingrezza, and tetrabenazine that would be added to this new class. She provided indications, actions, and dosing for the agents. Dr. LeCheminant noted that Ingrezza and Austedo already had prior authorization criteria placed from the DUR Board.</p> | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| | <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p> | <p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Crumby seconded the motion.</p> <p>Board Member Khurana inquired about the prior authorization criteria associated with Ingrezza and Austedo. Dr. LeCheminant displayed the criteria. Board Member Khurana asked how this Board might address the DUR Board if there are questions regarding the established criteria. He noted his concerns with delays in therapy regarding the criteria in place. Dr. LeCheminant noted that the criteria had not been reviewed since January of 2018 and stated she could bring the criteria back to the DUR Board for review and potential updating. Chairman Decerbo inquired how Board Member Khurana could relay his specific changes to the DUR Board. Mr. Gabriel Lither commented that Board Member Khurana could reach out directly to the DUR Board to provide thoughts as a prescriber providing feedback. Board Member Khurana noted that this Board has historically provided recommendations to the DUR Board. Mr. Lither stated that the Board can make a recommendation to the Board but may be difficult to relay to the Board depending on the number of changes recommended.</p> <p>A vote was held:</p> <table border="0" data-bbox="651 1120 1501 1409"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| | <p>Board Member Khurana made a motion to provide recommendations to the DUR Board to allow access to these agents with appropriate FDA-approved diagnosis(es).</p> <p>Chairman Decerbo seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 527 1501 803"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p> | <p>Dr. LeCheminant recommended Ingrezza, Austedo, and tetrabenazine be added to the PDL as preferred and Xenazine be added as non-preferred.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p> | <p>Chairman Decerbo moved to accept the recommendation.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 1144 1501 1412"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| 5. Established Drug Classes Being Reviewed Due to the Release of New Drugs | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| a. For Possible Action: Discussion and possible adoption of Genitourinary Agents - Bladder Antispasmodics | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| i. Public comment. | Telephonic and web comment was called for, and the phone lines were opened. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ii. Drug class review presentation by OptumRx. | <p>Dr. LeCheminant discussed indications, treatment recommendations, and available generics.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class | <p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="651 990 1501 1274"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iv. Presentation of recommendations for PDL inclusion by OptumRx. | Dr. LeCheminant recommended adding Gemtesa as non-preferred and moving Detrol and Detrol LA to preferred status. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|---|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| <p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p> | <p>Board Member Ward moved to accept the recommendation.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 418 1514 703"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>b. For Possible Action: Discussion and possible adoption of Hormones and Hormone Modifiers - Anti-Hypoglycemic Agents</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>i. Public comment.</p> | <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Dr. Emily Smith from Zealand Pharma for Zegalogue. Dr. Smith made herself available for questions as Zegalogue is a new agent.</p> <p>Comment was provided by Dr. Lisa Renda from Eli Lilly for Baqsimi. She asked for any questions regarding Baqsimi. No questions were asked.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>ii. Drug class review presentation by OptumRx.</p> | <p>Dr. LeCheminant discussed Glucagen and Zegalogue. She noted indications, class overview, and routes of administration.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|---|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class. | <p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 451 1501 735"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iv. Presentation of recommendations for PDL inclusion by OptumRx. | <p>Dr. LeCheminant recommended adding Zegalogue and Glucagen to preferred, moving Baqsimi to preferred, and moving Glucagon emergency kit to non-preferred.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL. | <p>Chairman Decerbo moved to accept the recommendation.</p> <p>Board Member Hautekeet seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 1068 1501 1352"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| c. For Possible Action: Discussion and possible | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|---|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| adoption of Neurological Agents - Anti-Migraine Agents - CGRP Receptor Antagonists | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| i. Public comment. | <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Dr. Renda from Eli Lilly supporting Emgality. She asked for any questions regarding the agent. None were asked at this time.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ii. Drug class review presentation by OptumRx. | <p>Dr. LeCheminant discussed indications, dosing, and efficacy of Qulipta. She noted that all agents in this class require prior authorization and that criteria for Qulipta would be presented to the DUR Board in January.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class. | <p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="653 1029 1503 1308"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iv. Presentation of recommendations for | <p>Dr. LeCheminant recommended Qulipta be added as preferred.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| PDL inclusion by OptumRx. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL. | <p>Chairman Decerbo noted that quantity limits would be presented to the DUR Board in January, which should help control utilization.</p> <p>Board member Ward motioned to accept the changes as presented.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="651 592 1501 878"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| d. For Possible Action: Discussion and possible adoption of Ophthalmic Agents - Ophthalmic for Dry Eye Disease | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| i. Public comment. | <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Dr. Sommers from Novartis regarding Xiidra. She requested Xiidra be moved to preferred. She discussed the pathogenesis of dry eye disease and the mechanism of action of Xiidra. Dr. Sommers discussed Xiidra's side effect profile.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ii. Drug class review presentation by OptumRx. | Dr. LeCheminant discussed Eysuvis. She noted the indication, dosing, and recommendations. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| | Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class. | <p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 527 1501 803"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iv. Presentation of recommendations for PDL inclusion by OptumRx. | Dr. LeCheminant recommended adding Eysuvis to non-preferred. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL. | <p>Chairman Decerbo noted that he would consider adding Xiidra to preferred given utilization and pricing.</p> <p>Chairman Decerbo moved to accept the recommendation with the additional movement of Xiidra to preferred.</p> <p>Board Member Hautekeet seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 1282 1501 1396"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | |
|--|--|--------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| | <table border="0"> <tr> <td data-bbox="663 240 932 269">Hautekeet, Mike, R.Ph</td> <td data-bbox="1184 240 1213 269"><input checked="" type="checkbox"/></td> <td data-bbox="1310 240 1339 269"><input type="checkbox"/></td> <td data-bbox="1436 240 1465 269"><input type="checkbox"/></td> </tr> <tr> <td data-bbox="663 282 968 311">Khurana, Sapandeep, MD</td> <td data-bbox="1184 282 1213 311"><input checked="" type="checkbox"/></td> <td data-bbox="1310 282 1339 311"><input type="checkbox"/></td> <td data-bbox="1436 282 1465 311"><input type="checkbox"/></td> </tr> <tr> <td data-bbox="663 324 856 354">Singh, Aditi, MD</td> <td data-bbox="1184 324 1213 354"><input checked="" type="checkbox"/></td> <td data-bbox="1310 324 1339 354"><input type="checkbox"/></td> <td data-bbox="1436 324 1465 354"><input type="checkbox"/></td> </tr> <tr> <td data-bbox="663 367 926 396">Ward, Kate, Pharm.D.</td> <td data-bbox="1184 367 1213 396"><input checked="" type="checkbox"/></td> <td data-bbox="1310 367 1339 396"><input type="checkbox"/></td> <td data-bbox="1436 367 1465 396"><input type="checkbox"/></td> </tr> </table> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | |
| <p>e. For Possible Action: Discussion and possible adoption of Psychotropic Agents - Atypical Antipsychotics- Long Acting Injectable</p> | | | | | | | | | | | | | | | | | | |
| <p>i. Public comment.</p> | <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Ms. Reedy from the mental health advocacy group NAMI. She discussed the familial impact when patients cannot maintain therapy on antipsychotics. She noted NAMI's support for all agents to be preferred and that NAMI continues to recommend open access.</p> | | | | | | | | | | | | | | | | | |
| <p>ii. Drug class review presentation by OptumRx.</p> | <p>Dr. LeCheminant discussed Invega Hafyera. She provided indication, dosing, and administration. She noted the noninferiority to Invega Trinza.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p> | | | | | | | | | | | | | | | | | |
| <p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p> | <p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>Board Member Khurana inquired about the prior authorization for the use of Trinza prior to Hafyera. Chairman Decerbo noted package insert indications.</p> <p>A vote was held:</p> | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|---|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| | <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iv. Presentation of recommendations for PDL inclusion by OptumRx. | Dr. LeCheminant recommended adding Invega Hafyera to preferred. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL. | <p>Board Member Ward moved to accept the recommendation.</p> <p>Board Member Crumby seconded the motion.</p> <p>A vote was held:</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| f. For Possible Action: Discussion and possible adoption of Psychotropic Agents - Atypical Antipsychotics - Oral/Topical | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| i. Public comment. | Telephonic and web comment was called for, and the phone lines were opened. Dr. LeCheminant noted letters submitted in public comment. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes |
|---|---|-------|
| | <p>Comment was provided by Dr. Phillip Rich, a psychiatrist from Reno with 41 years of experience. Dr. Rich discussed his utilization of Caplyta and the risk of weight gain with other agents. He requested Caplyta be moved to preferred.</p> <p>Comment was provided by Dr. Kenneth Berry from Alkermes to discuss Lybalvi. He noted indications, warnings, dosing, adverse events, and clinical efficacy data. He requested Lybalvi be moved to preferred.</p> <p>Comment was provided by Dr. Robert Lynn regarding the use of Caplyta. He noted that he has never been paid to use or speak for Caplyta. Due to drug interactions, once-daily dosing, and titration, he finds it useful in his patient population. Dr. Lynn requested Caplyta to be moved to preferred.</p> <p>Comment was provided by Dr. Jazmin Acosta from Intracellular Therapies for Caplyta. She provided clinical, safety, and tolerability of Caplyta.</p> | |
| <p>ii. Drug class review presentation by OptumRx.</p> | <p>Dr. LeCheminant discussed Lybalvi indications and clinical trial efficacy data. She noted Lybalvi's weight gain compared to olanzapine. She provided a summary of adverse events for the antipsychotic agents in this class. Dr. LeCheminant noted that the preferred agents do not require prior authorization unless the member is under 18 years of age. Non-preferred agents only require the failure of one preferred agent to receive. Six months of coverage of a non-preferred agent is permitted for those patients discharged from inpatient services to ensure time for stabilization with outpatient services.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p> | |
| <p>iii. Discussion by Board and action by Board to approve clinical/therapeutic</p> | <p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|-------------------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|-------------------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| <p>equivalency of agents in class.</p> | <p>A vote was held:</p> <table border="0" data-bbox="661 310 1501 586"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p> | <p>Dr. LeCheminant recommended adding Lybalvi to non-preferred, moving Geodon to preferred, and moving ziprasidone to non-preferred.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p> | <p>Board Member Khurana discussed that no agent on the preferred side has a similar combination to Lybalvi. He noted that he supports being cost-effective while providing ample preferred agents.</p> <p>Chairman Decerbo noted he appreciates that only one preferred agent is required for non-preferred utilization.</p> <p>Chairman Decerbo moved to accept the recommendation.</p> <p>Board Member Hautekeet seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 1175 1501 1414"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|---|-------------------------------------|--------------------------|----|-------|---------------------------------|--------------------------|-------------------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|--------------------------|-------------------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| | <p>Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Board Member Khurana moved to move Lybalvi and Caplyta to preferred.</p> <p>Chairman Decerbo seconded the motion.</p> <p>Board Member Khurana noted his concerns regarding side effect profiles.</p> <p>Board Member Ward inquired if these would be agents that would be utilized first-line. Board Member Khurana stated that he would utilize these agents first-line as appropriate. Board Member Ward asked if prior authorization criteria from the DUR Board would control the utilization of these preferred products. Board Member Khurana noted that it would be a rational approach, but not necessarily something he would want to have in place.</p> <p>Mr. Lither inquired if prior authorization was required for these agents or not. Dr. LeCheminant noted that the non-preferred agents do have a medical justification component. Board Member Khurana commented that real-life processing does not occur in this fashion.</p> <p>A vote was held:</p> <table data-bbox="661 1039 1543 1323"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| g. For Possible Action: Discussion and possible | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|---|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| adoption of Toxicology Agents – Antidotes- Opiate Antagonists | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| i. Public comment. | <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ii. Drug class review presentation by OptumRx. | <p>Dr. LeCheminant discussed Kloxxado and provided an overview of dosing, formulations, and frequency. She noted Zimhi would be reviewed for placement at a future SSSB meeting.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class. | <p>Chairperson Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="651 917 1501 1198"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iv. Presentation of recommendations for PDL inclusion by OptumRx. | Dr. LeCheminant recommended adding Kloxxado to preferred. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| v. Discussion by Board and action by Board | Chairman Decerbo moved to accept the recommendation. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| <p>for approval of drugs for inclusion on the PDL.</p> | <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 349 1501 625"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>6. Established Drug Classes Being Reviewed Due to the Release of New Generics</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>a. For Possible Action: Discussion and possible adoption of Analgesics - Analgesic Miscellaneous - Neuropathic Pain/ Fibromyalgia Agents</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>i. Public comment.</p> | <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>ii. Drug class review presentation by OptumRx.</p> | <p>Dr. LeCheminant discussed generic availability.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>iii. Discussion by Board and action by Board to approve clinical/therapeutic</p> | <p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| <p>equivalency of agents in class.</p> | <p>A vote was held:</p> <table border="0" data-bbox="661 272 1501 557"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p> | <p>Dr. LeCheminant recommended moving Lidoderm to preferred and pregabalin and pregabalin ER to non-preferred.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p> | <p>Chairman Decerbo moved to accept the recommendation.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 889 1501 1174"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>5. Established Drug Classes Being Reviewed Due to the Release of New Drugs</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>b. For Possible Action: Discussion and possible adoption of Cardiovascular</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| Agents – Antihypertensive Agents – Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| i. Public comment. | <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ii. Drug class review presentation by OptumRx. | <p>Dr. LeCheminant discussed current generic availability within this drug class.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class. | <p>Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="651 885 1501 1161"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iv. Presentation of recommendations for PDL inclusion by OptumRx. | <p>Dr. LeCheminant recommended adding enalapril solution to non-preferred.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| v. Discussion by Board and action by Board for approval of drugs | <p>Chairperson Decerbo moved to accept the recommendation.</p> <p>Board Member Crumby seconded the motion.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|---|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| for inclusion on the PDL. | <p>A vote was held:</p> <table border="0" data-bbox="661 310 1501 594"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 7. Established Drug Classes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| a. For Possible Action: Discussion and possible adoption of Hormone and Hormone Modifiers – Antidiabetic Agents – Incretin Mimetics Agents. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| i. Public comment. | <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Dr. Jonathan Delgado with Novo Nordisk asked for questions regarding Ozempic and Rybelsus. No questions were asked.</p> <p>Comment was provided by Dr. Renda with Eli Lilly asked for questions regarding Trulicity. No questions were asked.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ii. Drug class review presentation by OptumRx. | <p>Dr. LeCheminant discussed indications and current generic availability within this drug class.</p> <p>Dr. LeCheminant recommended the Board consider the class clinically and therapeutically equivalent.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| iii. Discussion by Board and action by Board to approve | <p>Chairperson Decerbo moved to accept the class as clinically and therapeutically equivalent.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|--------------------------|--------------------------|----|-------|---------------------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|-----------------------|-------------------------------------|--------------------------|--------------------------|------------------------|-------------------------------------|--------------------------|--------------------------|------------------|-------------------------------------|--------------------------|--------------------------|----------------------|-------------------------------------|--------------------------|--------------------------|--|
| <p>clinical/therapeutic equivalency of agents in class.</p> | <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 349 1501 625"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>iv. Presentation of recommendations for PDL inclusion by OptumRx.</p> | <p>Dr. LeCheminant recommended moving Trulicity to preferred.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p> | <p>Board Member Hautekeet moved to accept the recommendation.</p> <p>Board Member Singh seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="661 966 1501 1242"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> | | Yes | No | Abst. | Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | Yes | No | Abst. | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Decerbo, Mark, Pharm.D. – Chair | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Crumby, Mark, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hautekeet, Mike, R.Ph | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Khurana, Sapandeep, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Singh, Aditi, MD | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward, Kate, Pharm.D. | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>8. OptumRx Reports: New Drugs to Market and New Line Extensions</p> | <p>Dr. LeCheminant reviewed tezepelumab, a new drug indicated for the treatment of severe asthma. Dr. LeCheminant reviewed levoketoconazole for the treatment of Cushing’s syndrome. She reviewed antiretroviral agents cabotegravir, indicated for PrEP, and lenacapavir, indicated for the treatment of multidrug-resistant HIV-1 infection.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Agenda Item | Record | Notes |
|---|--|---|
| 9. Closing Discussion | | |
| a. Public comments on any subject. | <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p> | |
| b. Date and location of the next meeting. | Chairman Decerbo confirmed the next meeting is scheduled for March 24, 2022, and will be at the JW Marriott. | <p>The meeting location has been moved to: Hampton Inn Tropicana. 4975 S. Dean Martin Dr. Las Vegas, Nevada, 89118</p> |
| c. Adjournment. | Chairman Decerbo adjourned the meeting at 3:54 PM. | |

Attachment A – Members of the Public in Attendance














Acosta, Jazmin, Intracellular Therapies
Alegria, Veronica, DHCFP
Ashton, Elisa, Johnson & Johnson
Belz, Jeanette, Belcase
Beranek, Thomas, Centene
Berry, Kenneth, Alkermes
Bitton, Ryan, HPN
Breen, A
Capen, Maribeth, WellPoint
Carter, Morgan, Artia Solutions
Colabianchi, Jeana, Sunovion
Cooper, Christa
Cummings, Sarah, Dungarvin
De Rosa, Regina, WellPoint
Delap, Terry, GSPNV
Delgado, Jonathan, Novo Nordisk
Diebes, Tressa, Takeda
Droese, Ben, Amgen
Duerre, Mark, Intercellular Therapies
Germain, Joe, Biogen
Gorzynski, Andy
Groppenbacher, Shannon, Johnson & Johnson
Grothe, Deron, Teva Pharma
Hartman, Nena, Neurocrine
Hawkins, Tina, Magellan
Horne, Dr. Robert
Kerr, Camille, Regeneron
Large, David
Leroue, Chelsea, Biohaven Pharma
Levin, Dr. Amy, WellPoint

Lim, Luke, WellPoint
Lovan, Charlie, AbbVie
Nguyen, Bao, Johnson & Johnson
Oliver, Carmen, Biohaven Pharma
Ou, Karen, Gilead
Paiewonsky, Ed, Neurocrine Biosciences
Pearce, Robert
Powell, Natasha, WellPoint
Reedy, Robin
Renda, Lisa, Lily
Rich, Dr. Phillip
Ritter, Jean
Roa, Ryan, Merck
Roy, Melissa
Shear, Jennifer, Teva Pharma
Smith, Emily, Zealand Pharma
Smith, Jason, Gilead
Sommers, Melissa, Novartis
Sullivan, Mike, Amgen
Thompson, La’Kendrick, Dungarvin
Walter, Lindsey, Novartis
Wensel, Brian, Sunovion
Willie, Brad, Neurocrine Biosciences
Yang, Rochelle, Teva Pharma
Zarob, Michael, Alkermes

Attendees with no last name available:

Amy
BN

Attachment B – Submitted Written Comment

-  11.29 Caplyta Dr Stoll
-  12.08 Nurtec Lisa Hammargen
-  12.09 Rachel Gardner Nurtec
-  1805_001
-  caplyta letter
-  caplyta letter of support to nevada medicaid committee, nov 2021
-  Caplyta letter
-  CCF_000282
-  Dr. Paul Nguyen- Caplyta
-  Dr. Sullivan
-  Scan Dec 7, 2021
-  SSSB_Public_Comment_Caplyta_Malinas
-  SSSB_Public_Comment_Ingrezza_Malinas